SeaPRwire

Acme, Founder of ACET, Calling on Thailand’s Embrace of Digital Assets

London, United Kingdom – November 30, 2024 – (SeaPRwire) – Recently, ACET celebrated reaching 150,000 holders worldwide. ACET founder Worawat “Acme” Narknawdee the 36-year old visionary Billionnaire, financial innovator, investor, and entrepreneur is calling on the Thai government to embrace Bitcoin as part of its international reserve fund. The Possibility of Bitcoin as Thailand’s Reserve Fund Acme believes that Bitcoin is no longer just a digital currency, but a force poised to transform the global economy. With Bitcoin’s market value surging to unprecedented heights, Acme argues that now is the time for Thailand to position itself as a leader in the digital age. Acme envisions Bitcoin as an indispensable asset that can help Thailand diversify its financial reserves, improve economic stability, and lead the way in blockchain innovation. While the volatility and regulatory concerns surrounding Bitcoin are valid, Acme believes these obstacles are surmountable with proper education, infrastructure, and regulatory reform. “Thailand stands at a crossroads,” Acme explained. “The future of money is digital, and Bitcoin is the key to unlocking the potential of a fully digital economy. By taking bold steps today, Thailand can lead the region and set the stage for long-term prosperity in the global digital economy.” “Bitcoin is more than a currency,” said Acme. “It is a revolutionary technology that can drive the future of finance, and Thailand has the potential to lead this charge.” His proposal is to integrate Bitcoin into Thailand’s reserves to enhance economic diversification, improve resilience against global volatility, and ultimately fuel the country’s digital economy. This strategic move could place Thailand at the forefront of blockchain technology and digital currency adoption in Southeast Asia. The Bold Path Forward Acme’s proposal may seem daring, but it offers an opportunity for Thailand to embrace the future, tapping into the transformative power of Bitcoin and blockchain technology. As the world increasingly moves toward a digital-first economy, Thailand’s decision to integrate Bitcoin into its reserves could serve as a catalyst for long-term growth and innovation, attracting global investment and positioning the nation as a true leader in the digital era. About Acme, Founder of ACET Since 2012, Acme has not only been an avid investor but also the largest Bitcoin holder in Thailand. While the exact number of BItcoins owned by Mr. Worawat has not yet been disclosed, sources from the crypto community estimated he was holding at least  11,000 BTC, more thn twice the amount of Bitcoins held by the Government of El Salvador, which declared Bitcoin as a legal tender in 2021. His commitment to the cryptocurrency ecosystem has shaped him into a thought leader in the space. In 2021, Acme solidified his place in the global fintech arena by launching ACT (ACET), a cryptocurrency coin that now boasts over 150,000 holders worldwide, with a total market value of more than $300 million USD. Acme’s influence extends beyond business. Known for his philanthropy, he has held two record-breaking Bitcoin giveaways, in 2017 and 2021, where he gifted a combined total of 16 Bitcoins (worth over 1.5 million USD at today’s prices) to fans, promoting cryptocurrency education and awareness. His commitment to sharing knowledge and empowering others has made him a household name in Thailand’s crypto community and beyond. Social Links X: https://x.com/ACTDeFansFi Facebook: https://www.facebook.com/ACTDeFansFi/ Telegram: https://t.me/ACTAcet Github: https://acet-finance.gitbook.io/act Media contact Brand: ACET Contact:  Corporate Communication Division Email: media@acet.finance Website: https://acet.finance/ The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

ACN Newswire

NEFECON(R) Included in National Reimbursement Drug List (NRDL)

HONG KONG, Nov 29, 2024 - (ACN Newswire via SeaPRwire.com) - On November 28, the National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security announced the "National Reimbursement Drug List (2024)" (NRDL), which will officially take effect on January 1, 2025. NEFECON(R), the first etiological treatment for IgA nephropathy developed by Everest Medicines, was successfully included in the NRDL. This milestone signifies a breakthrough in advancing the standardization of IgAN treatment and improving accessibility and affordability, offering hope for millions of IgAN patients in China. NEFECON(R) has been prescribed in mainland China since May this year and has been approved in Macau, Hong Kong, Taiwan, China, South Korea and in Singapore under the trade name Nefegan(R).NEFECON(R) is the first ever treatment for IgAN to receive full approval from the U.S. Food and Drug Administration (FDA) and the first non-oncology therapeutic to receive breakthrough therapy designation in China by the China National Medical Products Administration (NMPA), underscoring its globally leading position and exceptional clinical value. Recently, at the 2024 American Society of Nephrology (ASN) Annual Meeting, data from the open-label extension (OLE) phase of the NefIgArd Phase 3 trial demonstrated that patients undergoing a second course of NEFECON(R) treatment experienced similar benefits in estimated glomerular filtration rate (eGFR) preservation and proteinuria reduction as observed after the initial treatment, with good tolerance. These findings further validate the feasibility and efficacy of long-term treatment strategies, aligning with recommendations from the "KDIGO 2024 Clinical Practice Guideline for The Management Of Immunoglobulin A Nephropathy (IgAN) And Immunoglobulin A Vasculitis (IgAV)", highlighting NEFECON(R)'s innovation and clinical value in IgAN treatment. NEFECON(R) was also listed as the only treatment proven to reduce the levels of pathogenic forms of IgA and IgA immune complexes.IgAN is highly prevalent in Asia and is one of the main causes of kidney failure in young adults in China. Statistics show that with approximately 5 million IgAN patients in China and over 100,000 newly diagnosed patients annually, there is a significant unmet clinical demand. Since NEFECON(R)'s first prescription was issued in Mainland China in May 2024, the product has demonstrated strong market performance. According to Everest Medicines' interim report, NEFECON(R) achieved RMB1.673 billion in sales within its first month, reflecting widespread recognition of its therapeutic benefits and the significant demand for innovative therapies among Chinese patients.With NEFECON(R)'s successful inclusion in the NRDL, its accessibility and coverage in China are expected to increase significantly, driving sustained and robust commercial revenue growth for Everest Medicines. This milestone not only strengthens the company's leadership in nephrology but also injects new momentum into optimizing resource allocation and promoting synergistic development. As reimbursement coverage leads to expanded market penetration, this development is poised to be a key catalyst in unlocking the full value of the company's core products, further accelerating the reevaluation of its market potential.NEFECON(R) included in the NRDL is a testament to Everest Medicines' differentiated commercial strategy. Another core product, XERAVA(R) (eravacycline) is the world's first fluorocycline antibiotic for the treatment of complicated intra-abdominal infections, continues to excel in the field of complicated intra-abdominal infections. According to the recently released final report of the "Comprehensive Evaluation Project on the Clinical Application of Eravacycline", the drug demonstrated an impressive overall treatment effectiveness rate of 90.1%, further affirming its clinical value and safety. As of the first half of 2024, XERAVA(R) achieved cumulative sales of RMB2.33 billion, underscoring its strong market acceptance and potential.In the autoimmune disease portfolio, VELSIPITY(R) continues to make steady progress in its commercialization journey. In October, under the "Hong Kong and Macau Medicine and Equipment Connect" policy, VELSIPITY(R) received approval from the Guangdong Provincial Medical Products Administration and is now available for use in three designated medical institutions within the Greater Bay Area. Earlier this year, VELSIPITY(R) was also approved for use in Macau and Singapore. In addition, Everest Medicines recently submitted a new drug application (NDA) for VELSIPITY(R) in Hong Kong and plans to submit an NDA in Mainland China by the end of the year. As Everest Medicines' third commercialized product, VELSIPITY(R) is poised to become a key growth driver, with significant market potential expected to unfold as its adoption expands further.Everest Medicines continues to make significant strides in innovative R&D, with its proprietary mRNA development platform now fully localized. The company's first personalized mRNA cancer vaccine, EVM16, has Initiated an Investigator-Initiated Clinical Trial (IIT). Additionally, EVER001, a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor being developed globally for the treatment of renal diseases, marks another important advancement. Everest Medicines will host an investor call on December 4th to discuss the results of the Phase 1b/2a clinical study of EVER001 in primary membranous nephropathy, highlighting its potential to drive future growth.Driven by the inclusion of NEFECON(R) in the NRDL and the continued progress of its core pipeline, Everest Medicines' business model demonstrates its resilience and strength. The company remains steadfast in fulfilling its commitments to investors while strengthening market confidence in its innovation and long-term growth potential. With a diversified focus on renal, infectious, and autoimmune diseases, Everest Medicines is harnessing its robust commercialization platform to fuel growth, steadily advancing toward its vision of becoming Asia's leading global biopharmaceutical company. Copyright 2024 ACN Newswire via SeaPRwire.com.

JCN Newswire

Launch of Demonstration Test for CO2 Capture from Chemical Recovery Boilers at Paper Mills in Japan

TOKYO, Nov 29, 2024 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) and Hokuetsu Corporation, one of Japan's leading paper manufacturers, launched a CO2 capture demonstration test at Niigata Mill (Niigata City), in November. This demonstration test aims to capture CO2 from a chemical recovery boiler that produces the steam and electricity needed for paper manufacturing, by using MHI's "CO2MPACT™ Mobile(Note)", a compact CO2 capture system. This is the first case in which MHI's CO2 capture technology is being applied to the pulp and paper industry. This demonstration test will allow MHI to analyze and evaluate data for commercial application and accelerate decarbonization in this industry.Chemical recovery boilers use "black liquor" as their main fuel, which is generated as a by-product in the pulp production process, the raw material for paper. The wood chips are dissolved in a sodium-containing solvent known as "white liquor" to extract the pulp, and the white liquor component is recovered from the black liquor residue that remains after combustion and is re-circulated for reuse.As the need for decarbonization grows around the world, Japan is also actively engaged in decarbonization efforts in various industrial sectors. And the pulp and paper industry is one of them. This demonstration test is expected to provide the pulp and paper industry with a solution that contributes to further global environmental measures by directly capturing CO2 emissions in the production process.MHI Group has formally declared its intent to achieve carbon neutrality by 2040, and the Company is now working strategically to decarbonize both the energy demand and supply sides. A core element of the Company's "Energy Transition," which targets decarbonization on the energy supply side, is the development of a CCUS value chain integrating diverse sources of carbon emissions with modes for carbon storage and utilization. Going forward, MHI Group will continue to proactively promote its CCUS business worldwide, applying its proprietary CO2 capture technologies, contributing as a solutions provider to reducing greenhouse gas emissions on a global scale, and developing further solutions that contribute to environmental protection.For details of the "CO2MPACT™" series, see the following press release: www.mhi.com/news/240919.htmlAbout MHI Group's CO2 capture technologiesMHI Group has been developing the KM CDR Process™ (Kansai Mitsubishi Carbon Dioxide Recovery Process) and the Advanced KM CDR Process™ in collaboration with the Kansai Electric Power Co., Inc. since 1990. As of November 2024, the Company has delivered 18 plants adopting these processes. The Advanced KM CDR Process™ adopts the KS-21™ solvent, which incorporates technological improvements over the amine-based KS-1™ and offers superior regeneration efficiency and lower deterioration than the KS-1™, and it has been verified to provide excellent energy saving performance, reduce operation costs, and result in low amine emissions.For further information on MHI Group's CO2 capture plants:https://www.mhi.com/products/engineering/co2plants.htmlAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2024 JCN Newswire via SeaPRwire.com.

ACN Newswire

香港董事学会公布2024年董事嘉奖系列得主

香港, 2024年11月29日 - (亚太商讯 via SeaPRwire.com) - 香港董事学会昨晚在香港会议及展览中心举行的香港董事学会周年晚宴上公布2024年度董事嘉奖系列得奖者。奖项系列包括历来备受推祟的「杰出董事奬」及今年最新启动的「气候管治奖」。香港董事学会主席陶荣博士致辞并掀开晚宴序幕，亦邀请了大紫荆勋贤、香港特别行政区非官守议员郑慕智博士、中联办经济部徐卫刚部长、财经事务及库务局常任秘书长(财经事务)甄美薇女士, JP以及证券及期货事务监察委员会主席、会计及财务汇报局主席黄天佑博士，SBS ，JP​担任主礼嘉宾。今届报名参赛者十分踊跃，引发评审团热烈讨论。获奖者包括董事和董事会在内共19 名，充份演绎今年奖项主题「灵活领导 创意年代」真谛。获奖者不仅展现组织灵活性，更在严峻的营商环境和地缘政治紧张局势中发挥了领导者的远见、勇气和智慧。此外，董事们更承担起带领团队辨析气候变化所带来的危与机，以及对全球永续发展和人类福祉所带来的深远影响。以下为2024年度董事嘉奖系列得奖者:- 杰出董事简称「DYA」- 气候管治奖简称「CGA」排名以英文名称字母为序上市公司执行董事DYA陈伟明先生登辉控股有限公司CGA陈婉珊女士利记控股有限公司DYA傅帆先生中国太平洋保险（集团）股份有限公司CGA李伟梁先生恒安国际集团有限公司黄维义先生香港中华煤气有限公司DYA & CGA颜建国先生中国海外发展有限公司非执行董事DYA 钟瑞明博士中国中铁股份有限公司曾宪章博士TCL电子控股有限公司王一江教授TCL电子控股有限公司董事会DYA & CGA华润啤酒(控股)有限公司CGA香港中华煤气有限公司DYA & CGA中国平安保险（集团）股份有限公司CGA俄铝非上市公司执行董事DYA陈云美女士屈臣氏实业CGA郑文聪教授正昌科技(集团)有限公司郑世有博士工程师奥雅纳DYA柯家洋先生稳健医疗(香港)有限公司法定／非分配利润组织董事会DYA香港旅游发展局另获:董事会多元化卓越嘉许国际内部审计师协会（IIA）香港分会理事会另获:董事会多元化卓越嘉许前排的主禮嘉賓、官員以及香港董事學會的理事會成員一同和後排實至名歸的得獎者合照。香港董事学会董事嘉奖系列」「香港董事学会董事嘉奖系列」是香港董事学会（简称「学会」）举办的一个项目，包含两个奖项系列。第一个系列是「杰出董事奬」，自2001年举办，为首次在亚洲的创举。由于董事最终负责企业管治，以及带领公司实现繁荣和诚信，该奖项宗旨为彰显杰出董事会和董事，并推广优秀企业管治和董事专业行为。该奖项现已成为学会每年推动具影响力的一个社区项目，并得到100多个合作伙伴的支持。迄今，255位获奖者已因在企业管治和董事常规中展现卓越的标准而受到表彰。2024年启动的「气候管治奖」构成学会奖项的第二个系列。该奖项着眼于彰显及启发董事及董事会在气候管治的优秀成就，并提倡董事们采取有关气候的行动。首届获奖者共10位。现在是董事必须在董事会议程和管治职务中处理因气候变化带来风险和机遇的关键时刻。候选人可由公众提名，其资料透过严格的程序进行处理，经过与甄选顾问作高度尽职调查的会面，最后由拥有高标准和公正判断的独立评审团选出。奖项按公司类别，即上市公司、非上市公司和法定/非分配利润组织，亦按职务，即执行董事、非执行董事和董事会，进行颁发。香港董事学会（简称"HKIoD"，又以下简称「学会」）香港董事学会为香港代表董事共同努力的首要组织，其宗旨是促进企业永续发展职能，为所有公司、其拥有者、持份者、人类以至地球创造持久价值；为达成使命，学会致力于企业管治（「企业管治」又称「公司治理」）及董事专业行为上的倡导及厘定相关标准。学会于1997年由创会主席郑慕智博士带领下创始，多年来非常荣幸获得香港特别行政区行政长官担任学会赞助人。学会会员来自不同行业及公司类别，并包括执行董事、非执行董事、独立非执行董事。学会以多元文化及国际视野进行会务，举办活动包括董事培训课程、研讨会与论坛、董事立场喉舌、指引设定、公众教育、董事嘉奖系列、上市公司管治水平厘定等。作为「董事学会环球网络」（Global Network of Director Institutes 简称"GNDI")的成员组织，学会投入全球性联手推动优秀企业管治及董事专业行为。学会亦获委派代办「气候管治行动」(Climate Governance Initiative)之香港分部，该行动是与「世界经济论坛」（World Economic Forum）合作的环球网络，积极促进董事们处理气候变化带来的风险与机遇。详情请浏览：http://www.hkiod.com|http://www.gndi.org|https://climate-governance.org/新闻垂询：董事嘉奖系列奖查询：纵横公共关系顾问集团有限公司香港董事学会陈练 +852 2114 4396 / brenda.chan@sprg.com.hk苏佩君 +852 2889 9986/ odessa.so@hkiod.com Copyright 2024 亚太商讯 via SeaPRwire.com.

ACN Newswire

领跑行业 顺丰控股港股IPO助力国际化发展提速

香港, 2024年11月29日 - (亚太商讯 via SeaPRwire.com) - 据星岛日报报道，自9月份以来，港股IPO市场持续回暖，大型IPO接连涌现。于11月27日港股上市的顺丰控股股份有限公司（「顺丰控股」，股份代号：6936.HK）也是其中之一，并成为港股市场最大的物流领域上市企业。本次IPO，公司计划将募集资金的约45%用于增强其国际及跨境物流能力。不难看出，H股上市，是顺丰控股全球化战略的重要一步，旨在利用全球资本，谋求更广阔的发展空间。从1到N 持续领跑行业发展自1993年公司创立以来顺丰控股于中国提供时效快递服务，以其创新的服务模式，在时效快递市场确立领先优势，树立了良好的品牌形象。依托在时效快递市场资源优势，公司不断捕捉客户日益变化的寄递需求，以边际成本孵化新业务，革新行业服务标准，将业务范围延伸至快运服务、冷运物流服务、同城即时配送服务、供应链服务及国际物流服务等领域，从中国辐射至亚洲乃至全球市场，成为一家全球领先的综合物流服务提供商，亦登榜《财富》世界500强企业。2024年获评《财富》最受赞赏的中国公司第二位，这也是顺丰连续8年上榜「《财富》最受赞赏的中国公司」。得益于业务范围拓宽和区域覆盖广度的提升，顺丰控股持续扩大其市场份额，并实现高于行业的增速，盈利能力持续增强。2021年至2023年，其收入增速及利润及息税折旧与摊销前利润增速均位列全球四大综合物流服务提供商第一。2024年前三季度，公司延续增长态势，收入同比增加9.4%，归母净利润同比增加21.6%。其中单三季度收入同比增加12.1%，归母净利润同比增加34.6%。值得一提的是，多重因素带动顺丰盈利强劲增长。公司经营现金流持续向好，并随着公司度过了资本支出的高峰期，自由现金流不断走强。2021年至2023年，公司自由现金流由负转正提升至144亿元。伴随规模经济效应、新业务盈利增长、成本结构及资产利用率优化，公司正步入高质量可持续发展轨道。抢滩国际市场 拓展业绩增量空间虽然当前国内快递市场增长速度开始放缓，但受中国企业出海、全球企业重塑供应链、以及跨境电商的推动，使得国际物流市场显示出强劲的增长动力。除中国地区外的亚洲市场，在区域内供应链重要性提升、跨境电商崛起、政策支持及贸易的共同驱动下，预计2023年至2028年物流支出复合年增长率将达到6.9%。此外，随着客户业务日趋复合多元化，领先的综合物流企业能够更好满足客户需求，在市场竞争中更具优势。面对市场机遇，顺丰控股近年来持续扩大物流网络，以抢占增长高地。公司运营亚洲最大的空运机队和陆运车队，并已开始运营鄂州货运枢纽的分拣及转运中心这一亚洲第一、全球第四座以货运为主的物流枢纽，以此进一步扩大国际网络覆盖能力，为国际物流服务提供有力支持。此外，顺丰控股还通过外延并购不断强化其国际物流服务能力。以2021年收购嘉里物流为例，此次收购不仅增强了其在东南亚本土及跨境快递、国际供应链和国际货代能力，还提升了其国际综合物流能力，扩大亚洲客户基础，进一步夯实其全球化发展的基础。通过香港上市，顺丰控股可藉助香港这一国际金融平台，吸引更多国际资本，提升其在国际市场的竞争力和品牌影响力，实现国际业务的加速拓展，释放长期投资价值。作为成长确定性较高的行业龙头，其未来发展值得期待。 Copyright 2024 亚太商讯 via SeaPRwire.com.

Latest News

叙利亚激进分子攻势的时机引发疑问——土耳其专家 “`

(SeaPRwire) -   基地组织盟友在以色列和真主党停火后袭击了阿勒颇 安卡拉全球咨询集团创始人、国际关系学教授侯赛因·巴吉奇告诉RT，叙利亚的伊斯兰武装分子在以色列和真主党停火生效后立即发动攻势，这很有意思。 此前被称为努斯拉阵线的恐怖组织叙利亚征服阵线（HTS）周三对阿勒颇市发起了大规模袭击。过去两天是该地区自2020年以来战斗最激烈的时候。 巴吉奇周四在接受RT采访时，将这场战斗描述为“非常危险的局势”，并表示叙利亚军队需要夺回领土，而且需要迅速行动。 “未来几天将出现一种新型联盟，”他预测说，土耳其、叙利亚和俄罗斯将联手对抗基地组织关联的武装分子。 据巴吉奇说，“外部势力”有兴趣加剧叙利亚的冲突。他提到了美国、以色列和“某些欧洲国家”。 巴吉奇说，土耳其最初支持2011年试图推翻大马士革政府的叛军，并强调安卡拉此后改变了其做法，并支持叙利亚的领土完整。 巴吉奇说，如果HTS武装分子壮大，这将给土耳其、叙利亚和俄罗斯带来问题，并可能引发另一波移民涌入欧洲。叙利亚冲突始于2011年，当时在美利坚合众国和几个邻国的支持下，叛军试图推翻大马士革总统巴沙尔·阿萨德的政府。 到2014年，伊斯兰国（IS，也称为ISIS）武装分子利用混乱的机会占领了叙利亚和伊拉克的大片地区。 在俄罗斯、伊朗和真主党的支持下，叙利亚政府军以及在美军的支持下库尔德军队最终将伊斯兰国的“哈里发国”缩小到小的抵抗据点。与此同时，其余非IS武装分子被推回伊德利卜省，在那里他们依赖安卡拉的保护。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

Latest News

西班牙警方捣毁乌克兰无人机贩毒集团

(SeaPRwire) -   据称使用了两个“毒品无人机”从摩洛哥运送大麻 马德里当局宣布，西班牙警方已经捣毁了一个贩毒集团，“利用乌克兰制造的‘毒品无人机’从摩洛哥走私大麻”。 直布罗陀海峡最窄处不到15公里宽，西班牙当局长期以来一直在努力阻止来自北非的走私者。虽然船只可以运载更多货物，但它们也更容易被拦截——不像无人机。 国家警察在周四的一份声明中说：“这些‘毒品无人机’是在乌克兰制造的，然后通过公路运送到我们国家的南部。” 这些无人机被直布罗陀海峡地区和太阳海岸的犯罪集团使用。在阿尔赫西拉斯和马贝拉进行了六次搜查，在警方行动中逮捕了十人。警方说，其中七人已被监禁。 据马德里方面称，这项名为“飓风行动”的调查得到了欧洲刑警组织以及乌克兰和波兰警方的支持。 🚩Desmantelada en una red de "narcodrones” que operaba entre y 👉Las aeronaves eran fabricadas en y trasladadas por carretera hasta nuestro país para su uso por organizaciones criminales asentadas en el y en la… — Policía Nacional (@policia) 警方总共查获了三架无人机，两架正在运行，一架仍在建造中。警方表示，这些乌克兰制造的无人机每次飞行最多可携带10公斤大麻，航程约为50公里。这使得它们能够从摩洛哥飞入西班牙南部，并在无需降落的情况下投下有效载荷。 虽然嫌疑人的身份尚未透露，但警方表示，这些无人机是由“来自东欧国家的个人”代表当地有组织犯罪集团操作的。在为期一年的调查过程中，走私者据称利用无人机运送了“多达一千公斤”的毒品。 据《国家报》(El Pais)报道，西班牙南部的毒品走私者长期以来一直使用创新的手段来躲避警方。虽然传统上用于走私毒品的快艇每次旅行可以运载更多货物，但它们也更容易被发现和拦截。 这并非第一次使用无人机从摩洛哥运送毒品。2021年7月，马拉加警方捣毁了一个同样位于太阳海岸的法国有组织犯罪集团。他们使用的是一架大型无人机，最多可载重150公斤，但它必须降落才能交付货物。 2022年，一对居住在加的斯的父子因建造能够携带150-200公斤毒品的水下无人机并与各种国际犯罪组织分享该技术而被捕。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

Latest News

俄罗斯在乌克兰冲突中获胜——北约成员国安全官员

(SeaPRwire) -   波兰国家安全局局长雅采克·谢维埃拉希望唐纳德·特朗普政府将确保西方不会战败 波兰一位高级安全官员表示，俄罗斯正在赢得乌克兰冲突的胜利，并补充说，他相信美国当选总统唐纳德·特朗普不会允许“西方世界”战败。 负责华沙国家安全局（BBN）的雅采克·谢维埃拉在周四接受ZET电台采访时发表了上述言论。波兰是基辅在其对抗莫斯科的战争努力中的直言不讳的支持者。 “毫无疑问，主动权掌握在俄方手中，”他说。“如果我们将胜利定义为获得的领土数量，那么俄罗斯肯定正在赢得这场战争。” 尽管乌克兰在战场上遭遇挫折，但谢维埃拉不认为现在是北约国家向该国部署军队的时候。他表示，美国及其盟友应该继续提供军事援助，试图通过贸易限制来损害俄罗斯经济，并游说中国加入西方阵营。 该电台指出，他的立场得到了听众的认同，因为只有16%参与在线投票的人支持在乌克兰部署北约地面部队。 在评论可能的冲突结果时，国家安全局局长承认，目前莫斯科几乎没有理由为了谈判解决而放弃其目标。谢维埃拉希望特朗普在1月份上任后可能会改变这种情况。 “我相信当选总统圈子里的人坚信，这场冲突不能以西方世界的失败而告终，”他说。 莫斯科认为乌克兰冲突是美国主导的对俄罗斯的代理人战争，在西方国家授权基辅使用捐赠的武器对该国境内深处发动远程袭击后，这场冲突已演变成事实上的全球对抗。 俄罗斯总统弗拉基米尔·普京表示，乌克兰军方如果没有外国支持者的直接参与，就无法发射这些系统。 因此，俄罗斯领导人警告说，如果俄罗斯军方认为有必要，莫斯科保留攻击捐助国境内军事目标的权利。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。 ```

Latest News

男子因威胁杀害特朗普而被捕——媒体报道

(SeaPRwire) -   据报道，曼努埃尔·塔马约-托雷斯被指控“几乎每天”发布威胁视频 据美国广播公司新闻（ABC News）周三报道，援引起诉书内容，美国联邦当局逮捕了一名男子，该男子涉嫌威胁杀死当选总统唐纳德·特朗普及其家人。 亚利桑那州居民曼努埃尔·塔马约-托雷斯周一在加利福尼亚州圣地亚哥被捕，此前他在Facebook上发布了一系列视频，其中包括11月13日发布的一段视频，视频中他显然举起一把AR-15式步枪，并对某人和他的家人进行威胁。 这段视频已从网上删除，法庭文件中提供的文字记录中，被指控的目标姓名被涂黑，并被称作“个人1”。对他及其家人的威胁被描述为“含糊但直接”。 美国广播公司新闻表示，熟悉调查情况的消息人士证实，“个人1”指的是特朗普。 在11月21日发布在Facebook上的视频中，塔马约-托雷斯据称说：“你将死去。你的儿子将死去。你的全家都将死去……我要在你脸上打个洞。” 调查人员在起诉书中表示，这名男子在几个月内“几乎每天”发布“大量”视频，声称“个人1”绑架并性交易了他的孩子。然而，目前尚不清楚塔马约-托雷斯是否有孩子。 他发布的其他视频片段中，一段是8月23日在亚利桑那州格伦代尔的沙漠钻石竞技场（Desert Diamond Arena）拍摄的，当时特朗普在该战场州举行了竞选集会。他声称目睹“个人1”和特勤局特工绑架了他的女儿。 除了威胁总统或当选总统的指控外，塔马约-托雷斯还被指控在去年试图购买枪支时在联邦表格上做出多项虚假陈述。他据报在表格上表示自己没有重罪记录，而实际上他于2003年因袭击罪被判有罪，并且在法律上被禁止拥有枪支。 唐纳德·特朗普在7月份宾夕法尼亚州的一次竞选集会上险些丧命，当时一枚从约150米外射出的子弹擦过了他的耳朵。特勤局击毙了枪手，该枪手被确认为20岁的美国人托马斯·克鲁克斯（Thomas Crooks）。另一名企图暗杀者瑞安·劳斯（Ryan Routh）在9月被捕，此前他在特朗普拥有的佛罗里达州高尔夫球场设下埋伏。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。